Zoetis (NYSE:ZTS) Given New $200.00 Price Target at Piper Sandler

Zoetis (NYSE:ZTS) had its target price lowered by Piper Sandler from $210.00 to $200.00 in a report issued on Monday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Piper Sandler’s price objective indicates a potential upside of 16.65% from the stock’s current price.

ZTS has been the topic of a number of other reports. Leerink Partners started coverage on shares of Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price objective on the stock. Stifel Nicolaus reduced their price target on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. UBS Group assumed coverage on shares of Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 price target on the stock. Finally, Morgan Stanley reduced their price target on shares of Zoetis from $248.00 to $243.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 29th. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Zoetis currently has a consensus rating of “Buy” and a consensus price target of $214.00.

Zoetis Price Performance

Shares of NYSE ZTS traded up $0.02 during mid-day trading on Monday, hitting $171.45. 258,248 shares of the stock were exchanged, compared to its average volume of 2,527,902. The company has a market cap of $77.35 billion, a P/E ratio of 32.20, a PEG ratio of 2.77 and a beta of 0.90. The stock’s fifty day simple moving average is $169.26 and its two-hundred day simple moving average is $179.21. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. Zoetis has a twelve month low of $144.80 and a twelve month high of $200.53.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Mizuho Securities USA LLC lifted its holdings in Zoetis by 13,726.9% in the third quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company’s stock valued at $950,524,000 after buying an additional 4,829,815 shares during the period. Raymond James Financial Inc. bought a new stake in Zoetis in the 4th quarter worth about $196,651,000. International Assets Investment Management LLC boosted its stake in Zoetis by 41,235.7% in the third quarter. International Assets Investment Management LLC now owns 939,974 shares of the company’s stock valued at $183,652,000 after acquiring an additional 937,700 shares during the last quarter. Amundi boosted its stake in Zoetis by 46.2% in the fourth quarter. Amundi now owns 2,748,719 shares of the company’s stock valued at $453,355,000 after acquiring an additional 867,993 shares during the last quarter. Finally, Assenagon Asset Management S.A. boosted its stake in Zoetis by 296.9% in the fourth quarter. Assenagon Asset Management S.A. now owns 889,444 shares of the company’s stock valued at $144,917,000 after acquiring an additional 665,331 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.